Certara Enables Discovery Scientists to Accelerate Therapeutic Peptide Discovery with New D360 version

RADNOR, PA – 2026 年 4 月 23 日 – Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, today announced the release of D360™ version 26.0. D360 is an enterprise scientific informatics application that allows discovery teams to access, analyze, and visualize molecule and bioactivity data across therapeutic modalities to discover new medicines. More than 6,000 research scientists worldwide rely on D360 to shorten their design-make-test-analyze cycle.

The major highlight of D360 26.0 is expanded capabilities for peptide sequence alignment and the design of sequences with improved characteristics. These enhancements help scientists analyze and understand sequence-activity relationships (how changes in sequence affect a molecule’s properties and biological activity). This analysis is central to engineering safe and effective drugs.

Scientists can now readily create new sequences by combining information from known sequences to produce peptides with improved biological profiles. The new design sandbox area within the alignment viewer allows interactive creation and editing of virtual sequences within the context of the sequence alignment. Newly designed sequences can be promoted into datasets for further analysis and captured as design peptides which can be prioritized for synthesis to advance the project.

This release also improves support for branched peptides by improving the display of main and branch chains, with clearer labeling and viewer controls to focus on key regions. In addition to comparing sequences already stored in their database, scientists can also specify new sequences in HELM and BILN notation as references.

D360’s alignment viewer provides a design sandbox area where new sequences can be designed and created based on the best properties of known sequences.

• 工作流程增强：improved series/subsetting capabilities, annotation usability, and data handling consistency
• Platform & administration: new diagnostics tools, configurable limits, and additional data source options

To learn more, watch this webinar.